NCT03533257Phase 2Completed

Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease

Study sponsor: Amylyx Pharmaceuticals Inc. · AMLX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2020-10-22Actual
Enrollment · participants95Actual
Source updated2025-03-07Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview